Precigen, Inc. (NASDAQ:PGEN) Shares Bought by HighTower Advisors LLC

HighTower Advisors LLC lifted its stake in shares of Precigen, Inc. (NASDAQ:PGEN) by 186.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 192,144 shares of the biotechnology company’s stock after buying an additional 125,145 shares during the period. HighTower Advisors LLC owned approximately 0.08% of Precigen worth $179,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Traphagen Investment Advisors LLC purchased a new stake in Precigen in the third quarter valued at approximately $29,000. SG Americas Securities LLC raised its position in Precigen by 44.2% during the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after buying an additional 13,823 shares during the last quarter. AQR Capital Management LLC lifted its stake in Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 18,097 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Precigen by 86.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 25,681 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Precigen by 40.7% in the second quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 16,486 shares during the period. 33.51% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Precigen in a research report on Friday, November 15th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Precigen Trading Up 5.2 %

Precigen stock opened at $0.79 on Thursday. The firm has a market cap of $229.96 million, a PE ratio of -1.43 and a beta of 1.71. Precigen, Inc. has a 12 month low of $0.65 and a 12 month high of $1.93. The stock’s 50 day simple moving average is $0.84 and its two-hundred day simple moving average is $1.12.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.